ATE538783T1 - Zusammenstellung zur verbesserung der rezeptorwirkung - Google Patents

Zusammenstellung zur verbesserung der rezeptorwirkung

Info

Publication number: ATE538783T1
Authority: AT; Austria
Prior art keywords: composition; vitamin; receptor effect; improve receptor; paranoia
Prior art date: 2001-11-14

Application number

AT02780164T

Other languages

English (en)

Inventor

Amanda Kiliaan

Robert Hageman

Original Assignee

Nutricia Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-14

Filing date

2002-11-14

Publication date

2012-01-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19774312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE538783(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-11-14 Application filed by Nutricia Nv filed Critical Nutricia Nv

2012-01-15 Application granted granted Critical

2012-01-15 Publication of ATE538783T1 publication Critical patent/ATE538783T1/de

Links

OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 2
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract 2
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
206010012289 Dementia Diseases 0.000 abstract 1
208000023105 Huntington disease Diseases 0.000 abstract 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 abstract 1
206010033864 Paranoia Diseases 0.000 abstract 1
208000027099 Paranoid disease Diseases 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
208000028017 Psychotic disease Diseases 0.000 abstract 1
229930003779 Vitamin B12 Natural products 0.000 abstract 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
230000009286 beneficial effect Effects 0.000 abstract 1
FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
206010015037 epilepsy Diseases 0.000 abstract 1
229960000304 folic acid Drugs 0.000 abstract 1
235000019152 folic acid Nutrition 0.000 abstract 1
239000011724 folic acid Substances 0.000 abstract 1
230000001771 impaired effect Effects 0.000 abstract 1
229910052749 magnesium Inorganic materials 0.000 abstract 1
239000011777 magnesium Substances 0.000 abstract 1
230000006386 memory function Effects 0.000 abstract 1
230000004060 metabolic process Effects 0.000 abstract 1
229930182817 methionine Natural products 0.000 abstract 1
235000020777 polyunsaturated fatty acids Nutrition 0.000 abstract 1
239000002243 precursor Substances 0.000 abstract 1
RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract 1
201000000980 schizophrenia Diseases 0.000 abstract 1
230000035945 sensitivity Effects 0.000 abstract 1
208000019116 sleep disease Diseases 0.000 abstract 1
235000019163 vitamin B12 Nutrition 0.000 abstract 1
239000011715 vitamin B12 Substances 0.000 abstract 1
235000019158 vitamin B6 Nutrition 0.000 abstract 1
239000011726 vitamin B6 Substances 0.000 abstract 1
229940011671 vitamin b6 Drugs 0.000 abstract 1
150000003722 vitamin derivatives Chemical class 0.000 abstract 1
239000011701 zinc Substances 0.000 abstract 1
229910052725 zinc Inorganic materials 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Inorganic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Pain & Pain Management (AREA)
Biochemistry (AREA)
Anesthesiology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)

AT02780164T 2001-11-14 2002-11-14 Zusammenstellung zur verbesserung der rezeptorwirkung ATE538783T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
NL1019368A NL1019368C2 (nl)	2001-11-14	2001-11-14	Preparaat voor het verbeteren van receptorwerking.
PCT/NL2002/000731 WO2003041701A2 (en)	2001-11-14	2002-11-14	Preparation for improving the action of receptors

Publications (1)

Publication Number	Publication Date
ATE538783T1 true ATE538783T1 (de)	2012-01-15

Family

ID=19774312

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02780164T ATE538783T1 (de)	2001-11-14	2002-11-14	Zusammenstellung zur verbesserung der rezeptorwirkung

Country Status (13)

Country	Link
US (7)	US7384981B2 (de)
EP (7)	EP2340825A3 (de)
JP (1)	JP4290552B2 (de)
CN (1)	CN100379413C (de)
AT (1)	ATE538783T1 (de)
AU (3)	AU2002343241B2 (de)
CA (1)	CA2467065C (de)
CY (1)	CY1112502T1 (de)
DK (1)	DK1443920T3 (de)
ES (1)	ES2378063T3 (de)
NL (1)	NL1019368C2 (de)
PT (1)	PT1443920E (de)
WO (1)	WO2003041701A2 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7449451B2 (en) *	2001-08-29	2008-11-11	Premier Micronutrient Corporation	Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks
US6849613B2 (en)	2001-08-29	2005-02-01	Kedar N. Prasad	Multiple antioxidant micronutrients
GB0311081D0 (en) *	2003-05-14	2003-06-18	Btg Internat Limted	Treatment of neurodegenerative conditions
FI20060154A7 (fi)	2003-08-18	2006-05-11	Btg Int Ltd	Neurogeneratiivisten tilojen hoito
DE10340740A1 (de) *	2003-09-04	2005-03-31	Degussa Food Ingredients Gmbh	Physiologisch aktive Zusammensetzung auf Phosphatidylserin-Basis
EP1713463A4 (de) *	2004-01-19	2009-03-18	Martek Biosciences Corp	Reelin-mangel oder dysfunktion und relevante verfahren
WO2005112635A2 (en)	2004-05-13	2005-12-01	Massachusetts Institute Of Technology	Uridine effects on dopamine release
US7645795B2 (en) *	2004-09-21	2010-01-12	BodyBio, Inc	Method for treating amyotrophic lateral sclerosis
WO2006054757A1 (ja) *	2004-11-16	2006-05-26	Astellas Pharma Inc.	カスパーゼ阻害剤
GB0425932D0 (en) *	2004-11-25	2004-12-29	Btg Int Ltd	Structured phospholipids
US20060194723A1 (en) *	2005-02-28	2006-08-31	Rabinoff Michael D	Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
GB0504333D0 (en) *	2005-03-02	2005-04-06	Btg Int Ltd	Treatment of cytokine dysregulation
GB0504362D0 (en) *	2005-03-02	2005-04-06	Btg Int Ltd	Cytokine modulators
JP2006321742A (ja) *	2005-05-18	2006-11-30	Tokyo Medical & Dental Univ	睡眠改善薬
EP1888081B1 (de)	2005-05-23	2016-12-28	Massachusetts Institute of Technology	Zusammensetzungen mit pufa und anwendungsverfahren dafür
JP5967855B2 (ja) *	2005-06-30	2016-08-10	サントリーホールディングス株式会社	日中活動量の低下および／又はうつ症状の改善作用を有する組成物
US20070004639A1 (en) *	2005-07-01	2007-01-04	Bodybio, Inc.	Methods and compositions for treating Parkinson's disease
US20130131007A1 (en)	2005-09-07	2013-05-23	Bebaas, Inc.	Vitamin b12 compositions
WO2007030108A1 (en) *	2005-09-07	2007-03-15	Bebaas, Inc.	Vitamin b-12 compositions
EP1800675B1 (de)	2005-12-23	2011-05-18	N.V. Nutricia	Zusammensetzung enthaltend mehrfach ungesättigte Fettsäuren, Proteine, Mangan und/oder Molybden und Nukleotide/Nukleoside, zur Behandlung von Demenz
CN100512819C (zh)	2006-12-06	2009-07-15	深圳市儿童医院	无糖维生素口服液
US20090012039A1 (en) *	2007-03-16	2009-01-08	Stan Kurtz	Use of methylcobalamin nasal spray to treat disorders
ES2808406T3 (es) *	2007-06-26	2021-02-26	Nutricia Nv	Mejora de la memoria en sujetos con un mini examen del estado mental de 24-26
WO2009002145A1 (en)	2007-06-26	2008-12-31	N.V. Nutricia	Lipid composition for improving function of brain functioning
WO2009002148A1 (en) *	2007-06-27	2008-12-31	N.V. Nutricia	Food composition for prodromal dementia patients
WO2009002146A1 (en)	2007-06-26	2008-12-31	N.V. Nutricia	Supporting activities of daily living
IL187159A0 (en) *	2007-07-03	2009-02-11	Gur Megiddo	Use of metadoxine in relief of alcohol intoxication
JP5288365B2 (ja) *	2007-07-17	2013-09-11	学校法人東海大学	統合失調症の検査および治療
US20100292330A1 (en) *	2007-10-04	2010-11-18	Yuanlong Pan	Compositions and methods for enhancing cognitive function
CA2704371A1 (en) *	2007-11-01	2009-05-07	Wake Forest University School Of Medicine	Compositions and methods for prevention and treatment of mammalian diseases
US8343753B2 (en)	2007-11-01	2013-01-01	Wake Forest University School Of Medicine	Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
ES2697149T3 (es)	2007-12-20	2019-01-22	Nutricia Nv	Producto líquido que contiene nucleótidos/nucleósidos
EP2224930B1 (de)	2008-01-04	2016-06-15	Nestec S.A.	Zusammensetzungen mit ungesättigten fettsäuren und verbindungen zur freisetzung von stickoxid sowie ihre verwendung zur erweiterung kognitiver und ähnlicher funktionen
US20100168053A1 (en) *	2008-03-17	2010-07-01	Revitapop	Oral delivery system for methylcobalamin to treat disorders
US20090286750A1 (en) *	2008-05-16	2009-11-19	Kasubick Robert V	Use of ribose in lessening the clinical symptoms of aberrant firing of neurons
KR20110044968A (ko) *	2008-06-10	2011-05-03	디에스엠 아이피 어셋츠 비.브이.	식물 추출물 및 ｐｕｆａ 조합물
WO2010013242A1 (en)	2008-07-29	2010-02-04	Alcobra Ltd.	Substituted pyridoxine-lactam carboxylate salts
WO2010095926A1 (en)	2009-02-20	2010-08-26	N.V. Nutricia	Use of reveratrol for preserving cognitive functioning
DK2429317T4 (da) *	2009-04-17	2019-05-13	Natac Pharma S L	Sammensætninger med højt indhold af omega-3-fedtsyrer og med lavt indhold af phytansyre
WO2010137944A1 (en)	2009-05-27	2010-12-02	N.V. Nutricia	Treatment of hypercalcaemia
CN102481291B (zh)	2009-06-25	2015-10-21	阿尔考布拉有限公司	用于治疗、减轻症状、缓解、改善和预防认知疾病、障碍或病症的方法
WO2011021926A1 (en)	2009-08-21	2011-02-24	N.V. Nutricia	Regulating the amino acid pool used for the acute-phase protein synthesis
US20110223246A1 (en) *	2010-03-10	2011-09-15	Joar Opheim	Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source
WO2011121151A1 (es) *	2010-03-31	2011-10-06	Vegenat, S.A.	Suplemento alimenticio funcional especialmente destinado para la nutrición, prevención y mejora en casos de alteraciones neurológicas, neurodegenerativas o trastornos cognitivos
WO2012030208A1 (en) *	2010-09-03	2012-03-08	N.V. Nutricia	Method and preparation for the treatment or prevention of anxiety or neurogenesis
WO2012091542A1 (en) *	2010-12-28	2012-07-05	N.V. Nutricia	Combination of components for the prevention and treatment of frailty
FR2979543B1 (fr) *	2011-09-02	2014-01-24	Phythea	Composition pharmaceutique, nutraceutique ou alimentaire et son utilisation
WO2013066152A1 (en)	2011-10-31	2013-05-10	N.V. Nutricia	Method for improving executive function
US20150044138A1 (en) *	2012-03-02	2015-02-12	N.V. Nutricia	Method for improving functional synaptic connectivity
EP3623812B1 (de) *	2012-04-27	2022-03-02	The Board of Governors for Higher Education, State of Rhode Island and Providence Plantations	Automatisierte nichtinvasive elektrische steuersysteme zur überwachung von tierbedingungen
JP2016508769A (ja) *	2013-01-28	2016-03-24	コーニンクレッカフィリップスエヌヴェＫｏｎｉｎｋｌｉｊｋｅＰｈｉｌｉｐｓＮ．Ｖ．	医用画像処理
CN103610079A (zh) *	2013-11-28	2014-03-05	中国海洋大学	一种dha磷脂的使用方法
WO2015115885A1 (en) *	2014-01-31	2015-08-06	N.V. Nutricia	Method for reducing white matter lesions, white matter hyperintensities (wmh), leukoaraiosis or periventricular white matter disease in elderly
US10499682B2 (en)	2014-08-25	2019-12-10	New Age Beverage Corporation	Micronutrient formulation in electronic cigarettes
WO2017069613A1 (en)	2015-10-23	2017-04-27	N.V. Nutricia	Method for improving recognition and/or working memory in hyperphenylalanimenia and phenylketonuria patients
WO2017155387A1 (en)	2016-03-08	2017-09-14	N.V. Nutricia	Method for supporting memory function and/or cognitive function
WO2017155386A1 (en) *	2016-03-08	2017-09-14	N.V. Nutricia	Method for treating brain atrophy
CN106620648A (zh) *	2016-12-30	2017-05-10	山东景源生物科技有限公司	一种阻断帕金森患者淋巴细胞周期的药物及制备方法
CN109091410B (zh) *	2017-06-20	2021-08-10	北京斯利安药业有限公司	组合物、其用途、口腔用制剂及其制备方法
US20210252173A1 (en) *	2018-04-20	2021-08-19	Retrotope, Inc.	Stabilized polyunsaturated compounds and uses thereof
US11744833B2 (en)	2019-04-12	2023-09-05	LA PharmaTech Inc.	Pharmaceutical compositions and methods for treatment of insomnia
US11690849B2 (en)	2019-04-12	2023-07-04	LA PharmaTech Inc.	Method of treating dementia
US11318144B2 (en)	2019-04-12	2022-05-03	LA PharmaTech Inc.	Compositions and methods for treating Alzheimer's disease and Parkinson's disease
TW202143952A (zh) *	2020-04-13	2021-12-01	美商威望生命科學公司	Omega-3之遞送方法以及用於增強人體的視覺敏銳度和心智發展之維生素和礦物質的組成物
US11351179B1 (en)	2021-08-05	2022-06-07	LA PharmaTech Inc.	Pharmaceutical compositions and methods for treatment of psychiatric disorders
AU2022345465A1 (en)	2021-09-17	2024-03-21	N.V. Nutricia	Solid composition suitable as a nutritional composition or supplement for animals that suffer from brain related disorders, decline or diseases
WO2026008342A1 (en) *	2024-07-01	2026-01-08	N.V. Nutricia	Composition for improving sleep

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1325596A (en) *		1919-12-23		Solar heater
US2403971A (en) *	1941-03-31	1946-07-16	Rca Corp	Method of making mica capacitors
US2404676A (en) *	1942-10-08	1946-07-23	Stewart Warner Corp	Heating apparatus
US2403972A (en) *	1943-05-20	1946-07-16	Universal Oil Prod Co	Process for extracting an aromatic hydrocarbon from a mixture containing other hydrocarbons
AT225649B (de)	1961-07-19	1963-01-25	Schoeller Bleckmann Stahlwerke	Bohrgestängerohrverbindung, insbesondere zwischen Schwerstangen
DE3110560A1 (de) *	1981-03-18	1982-10-14	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen	"angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben"
ES8301593A1 (es) *	1981-11-16	1983-01-01	Union Ind Y Agro Ganader S A U	Procedimiento de obtencion de una leche humanizada adiciona-da de nucleotidos con destino a la alimentacion infantil.
JPH0748991B2 (ja) *	1984-08-29	1995-05-31	日本油脂株式会社	経管栄養組成物
JPH0669953B2 (ja)	1985-08-16	1994-09-07	日産化学工業株式会社	脳脊髄系神経栄養剤
GB8601915D0 (en)	1986-01-27	1986-03-05	Efamol Ltd	Pharmaceutical compositions
DE3603000A1 (de)	1986-01-31	1987-08-06	Milupa Ag	Neue polyensaeure-reiche fettmischung und deren verwendung bei der herstellung von saeuglingsnahrungen
US4921877A (en) *	1986-10-27	1990-05-01	Abbott Laboratories	Liquid nutritional formula for glucose intolerance
GB8714772D0 (en)	1987-06-24	1987-07-29	Efamol Ltd	Essential fatty acid compositions
JP2524217B2 (ja)	1988-04-18	1996-08-14	マルハ株式会社	脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
JPH0358926A (ja)	1989-07-27	1991-03-14	Taiyo Fishery Co Ltd	脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
JPH0394655A (ja) *	1989-09-06	1991-04-19	Otsuka Pharmaceut Co Ltd	栄養補給用組成物
US5200218A (en) *	1989-11-08	1993-04-06	Lasater Priscilla D	Composition for dog food
FR2657013B1 (fr) *	1990-01-18	1992-05-15	Medgenix Group Sa	Composition dietetique a base de polypeptides et acides amines.
JP3058926B2 (ja)	1991-01-09	2000-07-04	鐘淵化学工業株式会社	ユビデカレノン含有組成物およびその調製方法
JP3173844B2 (ja)	1992-03-03	2001-06-04	雪印乳業株式会社	生体組織内ω３系脂肪酸増加剤及びそれを含む栄養組成物
US5780039A (en)	1992-04-23	1998-07-14	Novartis Nutrition Ag	Orally-ingestible nutrition compositions having improved palatability
JPH0717855A (ja)	1992-09-02	1995-01-20	Maruha Corp	脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
DE4304394A1 (en)	1993-02-13	1993-09-02	Fresenius Ag	Prepn. for nourishment of oncological patients - comprises fats formulation contg. oleic acid, alpha-linolenic acid, etc., and opt. carbohydrate and proteins
EP0700303A4 (de) *	1993-05-28	1996-08-21	Abbott Lab	Enterales ernägrungsprodukt
US5403826A (en) *	1993-05-28	1995-04-04	Abbott Laboratories	Nutritional product for persons infected with human immunodeficiency virus
CA2164291C (en)	1993-06-09	2007-10-30	David John Kyle	Methods and pharmaceutical compositions useful for treating neurological disorders
GB9318611D0 (en) *	1993-09-08	1993-10-27	Sandoz Nutrition Ltd	Improvements in or relating to organic compounds
HUP9800049A3 (en)	1995-02-23	1999-01-28	Novartis Nutrition Ag	Amino acid compositions and use thereof in clinical nutrition, and use of the said amino acids for preparing pharmaceutical compns. for the diminution of tnf
JPH08231391A (ja)	1995-02-24	1996-09-10	Kanagawa Kagaku Kenkyusho:Kk	痴呆症状改善薬
GB9510037D0 (en) *	1995-05-18	1995-07-12	Sandoz Nutrition Ltd	Improvements in or relating to organic compounds
FR2737849B1 (fr) *	1995-08-18	1997-09-19	Boiron	Complement nutritionnel absorbable pour l'equilibre quotidien des seniors
US5612074A (en) *	1995-12-21	1997-03-18	Leach; Robin L.	Nutrient fortified food bar
US5882714A (en) *	1996-04-15	1999-03-16	The Iams Company	Queens milk replacer
US5891465A (en) *	1996-05-14	1999-04-06	Biozone Laboratories, Inc.	Delivery of biologically active material in a liposomal formulation for administration into the mouth
JP3576318B2 (ja)	1996-06-19	2004-10-13	明治乳業株式会社	核酸関連物質含有栄養組成物
US5895652A (en) *	1996-07-29	1999-04-20	Longevity Institute International	Method of metabolic adjuvanation and cellular repair
CN1109543C (zh)	1996-10-11	2003-05-28	斯卡里斯塔有限公司	包括二十碳五烯酸和/或十八碳四烯酸的药物制剂
FR2760358B1 (fr) *	1997-03-04	2000-07-28	Francois Ballester	Composition cosmetique et pharmaceutique revigorante, notamment permettant d'eviter aux cheveux de devenir blancs avec l'âge, et aussi de reprendre leur couleur d'origine s'ils sont deja blancs
WO1998048788A1 (en) *	1997-04-29	1998-11-05	Scotia Holdings Plc	Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
FR2762993B1 (fr) *	1997-05-06	1999-08-13	Inst Rech Biolog Sa	Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
EP0891719A1 (de) *	1997-07-14	1999-01-20	N.V. Nutricia	Narungszusammensetzungen mit Gehalt an Methionin
GB9715444D0 (en) *	1997-07-22	1997-09-24	Scotia Holdings Plc	Therapeutic and dietary compositions
FR2773484B1 (fr) *	1998-01-09	2001-03-30	Pierre Moreau	Nouvelles compositions a effet synergique entre micronutriments et substances d'origine vivante
WO1999037155A1 (en) *	1998-01-27	1999-07-29	Nutramax Laboratories, Inc.	Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and st. john's wort for the treatment of mental disturbances
US6048846A (en) *	1998-02-26	2000-04-11	Cochran; Timothy M.	Compositions used in human treatment
EP0960572A1 (de) *	1998-05-12	1999-12-01	N.V. Nutricia	Ernährungszusammensetzung zur Behandlung von Dekubitalgeschwüren
DK1140104T3 (da) *	1998-07-31	2008-01-21	Massachusetts Inst Technology	Behandling af Alzheimer's sygdom ved forögelse af cytidinniveauer in vivo
US6472378B2 (en) *	1998-08-31	2002-10-29	Pro-Neuron, Inc.	Compositions and methods for treatment of mitochondrial diseases
US7121352B2 (en)	1998-11-16	2006-10-17	Enventure Global Technology	Isolation of subterranean zones
AU6981001A (en)	1998-11-16	2002-01-02	Shell Oil Co	Radial expansion of tubular members
GB2344606B (en)	1998-12-07	2003-08-13	Shell Int Research	Forming a wellbore casing by expansion of a tubular member
ES2187115T3 (es) *	1999-01-20	2003-05-16	Nutricia Nv	Preparado para lactantes.
GB9901809D0 (en) *	1999-01-27	1999-03-17	Scarista Limited	Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
AU771884B2 (en)	1999-02-11	2004-04-08	Shell Internationale Research Maatschappij B.V.	Wellhead
AU770008B2 (en)	1999-02-25	2004-02-12	Shell Internationale Research Maatschappij B.V.	Mono-diameter wellbore casing
AU770359B2 (en)	1999-02-26	2004-02-19	Shell Internationale Research Maatschappij B.V.	Liner hanger
US6569857B1 (en) *	1999-05-03	2003-05-27	Drugtech Corporation	Dietary supplement
US6409175B1 (en)	1999-07-13	2002-06-25	Grant Prideco, Inc.	Expandable joint connector
GB9916536D0 (en) *	1999-07-14	1999-09-15	Scarista Limited	Nutritional or pharmaceutical compositions
US6796390B1 (en)	1999-09-21	2004-09-28	Shell Oil Company	Method and device for moving a tube in a borehole in the ground
US6479545B1 (en) *	1999-09-30	2002-11-12	Drugtech Corporation	Formulation for menopausal women
AU8003800A (en) *	1999-10-08	2001-04-23	Joyce Corinne Bechthold	Methods and compositions for treating neurobehavioral disorders
US7048067B1 (en)	1999-11-01	2006-05-23	Shell Oil Company	Wellbore casing repair
US7516790B2 (en)	1999-12-03	2009-04-14	Enventure Global Technology, Llc	Mono-diameter wellbore casing
CA2291959A1 (en) *	1999-12-08	2001-06-08	Alex P. Korn	A nutriceutical composition of l-carnitine, ubiquinone, n-3 polyunsaturated fatty acids and vitamins specifically formulated at pharmacological doses for the amelioration of the risk factors and symptoms of atherosclerosis-related illnesses
GB2373468B (en)	2000-02-18	2004-07-14	Shell Oil Co	Expanding a tubular member
US7226916B1 (en) *	2000-05-08	2007-06-05	N.V. Nutricia	Preparation for the prevention and/or treatment of vascular disorders
US7208180B2 (en) *	2000-05-08	2007-04-24	N.V. Nutricia	Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
EP1155620B1 (de) *	2000-05-18	2005-08-10	Q-mega healthcare A/S	Nahrungsergänzungsmittel mit Vitaminen, Mineralien und mehrfach ungesättigten Fettsäuren
FR2811056B1 (fr)	2000-06-30	2003-05-16	Vallourec Mannesmann Oil & Gas	Joint filete tubulaire apte a subir une expansion diametrale
GB2382367B (en)	2000-07-28	2004-09-22	Enventure Global Technology	Coupling an expandable liner to a wellbore casing
CA2414449C (en)	2000-07-28	2006-09-05	Enventure Global Technology	Liner hanger with slip joint sealing members
GB2399119B (en)	2000-09-18	2005-05-11	Shell Int Research	Forming a wellbore casing
GB2389597B (en)	2000-10-02	2005-05-18	Shell Oil Co	Plastically deforming and radially expanding a tubular member
GB2399849B (en)	2001-01-03	2005-03-30	Enventure Global Technology	Tubular expansion
CA2432030C (en)	2001-01-17	2009-08-18	Enventure Global Technology	Mono-diameter wellbore casing
GB2399579B (en)	2001-01-17	2005-06-29	Enventure Global Technology	Mono-diameter wellbore casing
GB0102021D0 (en)	2001-01-26	2001-03-14	E2 Tech Ltd	Apparatus
GB2403971B8 (en)	2001-02-20	2005-09-21	Enventure Global Technology	Mono-diameter wellbore casing
CA2438807C (en)	2001-02-20	2009-05-26	Enventure Global Technology	Mono-diameter wellbore casing
US6964969B2 (en) *	2001-04-19	2005-11-15	Mccleary Edward Larry	Composition and method for treating impaired or deteriorating neurological function
PT1390378E (pt) *	2001-04-30	2009-07-23	Trommsdorff Arzneimittel	Ésteres de uridina farmaceuticamente activos
GB0111282D0 (en) *	2001-05-09	2001-06-27	Laxdale Ltd	Potentiation of therapeutic effects of fatty acids
ATE291910T1 (de) *	2001-05-30	2005-04-15	Laxdale Ltd	Verwendung von coenzym q (ubiquinone) und eikosapentaensäure (epa) für die behandlung von non-hodgkin's lymphoma und psychiatrischen oder neurologischen erkrankungen
GB2409217B (en)	2001-08-20	2005-12-28	Enventure Global Technology	Apparatus for radially expanding tubular members including an adjustable expansion device
US6541043B2 (en) *	2001-08-28	2003-04-01	Dexgen Pharmaceuticals, Inc.	Method and synergistic composition for treating attention deficit/hyperactivity disorder
US20060243444A1 (en)	2003-04-02	2006-11-02	Brisco David P	apparatus for radially expanding and plastically deforming a tubular member
US20050103502A1 (en)	2002-03-13	2005-05-19	Watson Brock W.	Collapsible expansion cone
US20060266527A1 (en)	2003-04-07	2006-11-30	Enventure Global Technology	Apparatus for radially expanding and plastically deforming a tubular member
CA2459910C (en)	2001-09-07	2010-04-13	Enventure Global Technology	Adjustable expansion cone assembly
WO2004085790A2 (en)	2003-03-27	2004-10-07	Enventure Global Technology	Apparatus for radially expanding and plastically deforming a tubular member
US6620850B2 (en) *	2001-09-19	2003-09-16	University Of Florida	Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors
AU2002360373A1 (en)	2001-11-12	2003-05-26	Enventure Global Technlogy	Mono diameter wellbore casing
GB2398318B (en)	2001-12-10	2005-10-12	Shell Int Research	Isolation of subterranean zones
AU2002367348A1 (en)	2001-12-27	2003-07-24	Enventure Global Technology	Seal receptacle using expandable liner hanger
US7424918B2 (en)	2002-08-23	2008-09-16	Enventure Global Technology, L.L.C.	Interposed joint sealing layer method of forming a wellbore casing
US7377326B2 (en)	2002-08-23	2008-05-27	Enventure Global Technology, L.L.C.	Magnetic impulse applied sleeve method of forming a wellbore casing
EP1985796B1 (de)	2002-04-12	2012-05-16	Enventure Global Technology	Schutzhülse für Gewindeverbindungen für eine ausdehnbare Liner-Aufhängvorrichtung
CA2484966A1 (en)	2002-05-06	2003-11-13	Enventure Global Technology	Mono diameter wellbore casing
WO2003104601A2 (en)	2002-06-10	2003-12-18	Enventure Global Technology	Mono-diameter wellbore casing
GB2418217B (en)	2002-06-12	2006-10-11	Enventure Global Technology	Collapsible expansion cone
GB2417971B (en)	2002-07-19	2007-02-14	Enventure Global Technology	Protective sleeve for threaded connections for expandable liner hanger
AU2003253782A1 (en)	2002-07-29	2004-02-16	Enventure Global Technology	Method of forming a mono diameter wellbore casing
AU2003263859A1 (en)	2002-09-20	2004-04-08	Enventure Global Technology	Protective sleeve for expandable tubulars
AU2003275131A1 (en)	2002-09-20	2004-04-08	Enventure Global Technology	Cutter for wellbore casing
AU2003263864A1 (en)	2002-09-20	2004-04-08	Enventure Global Technlogy	Rotating mandrel for expandable tubular casing
AU2003270774A1 (en)	2002-09-20	2004-04-08	Enventure Global Technlogy	Bottom plug for forming a mono diameter wellbore casing
WO2004027205A2 (en)	2002-09-20	2004-04-01	Enventure Global Technlogy	Mono diameter wellbore casing
AU2003298954A1 (en)	2002-09-20	2004-03-29	Enventure Global Technlogy	Threaded connection for expandable tubulars
AU2003259881A1 (en)	2002-09-20	2004-04-08	Enventure Global Technology	Residual stresses in expandable tubular casing
GB2410280B (en)	2002-09-20	2007-04-04	Enventure Global Technology	Self-lubricating expansion mandrel for expandable tubular
WO2004053434A2 (en)	2002-12-05	2004-06-24	Enventure Global Technology	System for radially expanding tubular members
GB2433281B (en)	2003-01-27	2007-08-01	Enventure Global Technology	Lubrication system for radially expanding tubular members
GB2429482B (en)	2003-02-18	2007-09-26	Enventure Global Technology	Protective compression and tension sleeves for threaded connections for radially expandable tubular members
GB2415983B (en)	2003-02-26	2007-09-05	Enventure Global Technology	Apparatus for radially expanding and plastically deforming a tubular member
GB2415454B (en)	2003-03-11	2007-08-01	Enventure Global Technology	Apparatus for radially expanding and plastically deforming a tubular member
WO2004083594A2 (en)	2003-03-14	2004-09-30	Enventure Global Technology	Apparatus and method radially expanding a wellbore casing using an expansion mandrel and a rotary expansion tool
WO2004083593A2 (en)	2003-03-14	2004-09-30	Enventure Global Technology	Radial expansion and milling of expandable tubulars
CA2518453A1 (en)	2003-03-17	2004-09-30	Enventure Global Technology	Apparatus and method for radially expanding a wellbore casing using an adaptive expansion system
WO2004083592A2 (en)	2003-03-18	2004-09-30	Eventure Global Technology	Apparatus and method for running a radially expandable tubular member
GB2416177A (en)	2003-04-08	2006-01-18	Enventure Global Technology	Apparatus for radially expanding and plastically deforming a tubular member
GB2416556B (en)	2003-04-14	2007-07-25	Enventure Global Technology	Apparatus and method for radially expanding a wellbore casing and drilling a wellbore
GB2415988B (en)	2003-04-17	2007-10-17	Enventure Global Technology	Apparatus for radially expanding and plastically deforming a tubular member
GB2432385B (en)	2003-08-14	2008-05-21	Enventure Global Technology	Expandable tubular
CA2536623A1 (en)	2003-09-02	2005-03-10	Enventure Global Technology	A method of radially expanding and plastically deforming tubular members
GB2422164B (en)	2003-09-02	2008-04-09	Enventure Global Technology	Threaded connection for expandable tubulars

2001
- 2001-11-14 NL NL1019368A patent/NL1019368C2/nl not_active IP Right Cessation
2002
- 2002-11-14 EP EP10186303A patent/EP2340825A3/de not_active Withdrawn
- 2002-11-14 US US10/495,341 patent/US7384981B2/en not_active Expired - Lifetime
- 2002-11-14 EP EP02780164A patent/EP1443920B1/de not_active Revoked
- 2002-11-14 EP EP10186291A patent/EP2363125A1/de not_active Withdrawn
- 2002-11-14 AU AU2002343241A patent/AU2002343241B2/en not_active Expired
- 2002-11-14 JP JP2003543588A patent/JP4290552B2/ja not_active Expired - Lifetime
- 2002-11-14 CN CNB02827086XA patent/CN100379413C/zh not_active Expired - Lifetime
- 2002-11-14 WO PCT/NL2002/000731 patent/WO2003041701A2/en not_active Ceased
- 2002-11-14 AT AT02780164T patent/ATE538783T1/de active
- 2002-11-14 DK DK02780164.6T patent/DK1443920T3/da active
- 2002-11-14 EP EP10186330A patent/EP2338483A3/de not_active Withdrawn
- 2002-11-14 EP EP10186323A patent/EP2340826A3/de not_active Withdrawn
- 2002-11-14 EP EP10186262A patent/EP2340824A3/de not_active Withdrawn
- 2002-11-14 EP EP10186298A patent/EP2340827A3/de not_active Withdrawn
- 2002-11-14 CA CA2467065A patent/CA2467065C/en not_active Expired - Lifetime
- 2002-11-14 ES ES02780164T patent/ES2378063T3/es not_active Expired - Lifetime
- 2002-11-14 PT PT02780164T patent/PT1443920E/pt unknown
2006
- 2006-09-29 AU AU2006225161A patent/AU2006225161B8/en not_active Ceased
- 2006-09-29 AU AU2006225160A patent/AU2006225160B2/en not_active Expired
2008
- 2008-03-10 US US12/045,112 patent/US7888391B2/en not_active Expired - Lifetime
- 2008-12-01 US US12/325,356 patent/US20090104283A1/en not_active Abandoned
- 2008-12-01 US US12/325,327 patent/US8362078B2/en not_active Expired - Fee Related
2012
- 2012-03-16 CY CY20121100289T patent/CY1112502T1/el unknown
2014
- 2014-08-08 US US14/455,726 patent/US20150037309A1/en not_active Abandoned
2015
- 2015-02-27 US US14/634,368 patent/US9504712B2/en not_active Expired - Fee Related
2016
- 2016-10-31 US US15/338,751 patent/US9844525B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1443920B1 (de)	2011-12-28
DK1443920T3 (da)	2012-04-16
EP2340827A2 (de)	2011-07-06
EP2340826A3 (de)	2012-09-12
US8362078B2 (en)	2013-01-29
AU2002343241B2 (en)	2006-06-29
JP2005513010A (ja)	2005-05-12
EP2340824A3 (de)	2012-05-30
US20170042852A1 (en)	2017-02-16
US9504712B2 (en)	2016-11-29
US20050009779A1 (en)	2005-01-13
EP1443920A2 (de)	2004-08-11
AU2006225160B2 (en)	2008-08-21
HK1065480A1 (en)	2005-02-25
EP2338483A3 (de)	2012-05-23
PT1443920E (pt)	2012-03-21
US9844525B2 (en)	2017-12-19
EP2340825A2 (de)	2011-07-06
ES2378063T3 (es)	2012-04-04
EP2340825A3 (de)	2011-09-07
EP2340824A2 (de)	2011-07-06
EP2338483A2 (de)	2011-06-29
WO2003041701A3 (en)	2004-03-18
US20150164945A1 (en)	2015-06-18
AU2006225161A8 (en)	2009-05-07
CN1615128A (zh)	2005-05-11
US20150037309A1 (en)	2015-02-05
US20090104283A1 (en)	2009-04-23
CA2467065C (en)	2010-08-17
AU2006225161B2 (en)	2009-04-23
WO2003041701A2 (en)	2003-05-22
EP2340826A2 (de)	2011-07-06
EP2340827A3 (de)	2012-11-14
US7384981B2 (en)	2008-06-10
US20080152726A1 (en)	2008-06-26
EP2363125A1 (de)	2011-09-07
JP4290552B2 (ja)	2009-07-08
AU2006225160A1 (en)	2006-10-19
NL1019368C2 (nl)	2003-05-20
AU2006225161B8 (en)	2009-05-07
CY1112502T1 (el)	2015-12-09
CA2467065A1 (en)	2003-05-22
AU2006225161A1 (en)	2006-10-19
US20090081179A1 (en)	2009-03-26
CN100379413C (zh)	2008-04-09
US7888391B2 (en)	2011-02-15

Publication	Publication Date	Title
ATE538783T1 (de)	2012-01-15	Zusammenstellung zur verbesserung der rezeptorwirkung
ATE381894T1 (de)	2008-01-15	Zubereitung zur vorbeugung und behandlung von gefässkrankheiten
IL183551A0 (en)	2007-09-20	Finishing set for a floor covering and holder, as well finishing profile, for a finishing set, and method for manufacturing a finishing profile and a skirting board
SI1511710T1 (sl)	2014-04-30	Spojine, sestavki in postopki za zdravljenje amiloidnih bolezni in sinukleinopatij, kot je Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsova bolezen
BRPI0408910A (pt)	2006-03-21	composto, composição farmacêutica e métodos para a profilaxia ou o tratamento de doenças ou condições e para a produção de uma composição farmacêutica
AU2003296341A8 (en)	2004-06-30	System and method for treating Parkinson's Disease and other movement disorders
EP1532985A4 (de)	2008-04-16	Verfahren zur herstellung einer zusammensetzung mit verz gerter freisetzung
MA27590A1 (fr)	2005-11-01	Agonistes du recepteur du facteur de liberation 2 de la corticotropine.
HRP20050742A2 (en)	2006-09-30	3-methyl-2-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis
WO2005040828A3 (en)	2005-06-16	Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
WO2006042137A3 (en)	2007-02-01	Methods for identifying parkinson's disease therapeutics
WO2005050225A3 (en)	2005-07-07	Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
WO2005040825A3 (en)	2005-06-30	Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
WO2005059546A3 (en)	2006-02-23	Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35)
WO2004038405A3 (en)	2004-09-30	Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
EP1769089A4 (de)	2009-04-15	Verfahren und zusammensetzungen für die prä- oder postsymptomatische diagnose von alzheimer und anderen neurodegenerativen erkrankungen
DE60325468D1 (de)	2009-02-05	Enol-tautomer der 3-indol-brenztraubensäure in fester und im wesentlichen reiner form zur behandlung von erkrankungen des zentralen nervensystems
WO2004042405A3 (en)	2004-09-23	Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 3 (gpr3)
WO2004038421A3 (en)	2004-06-24	Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)
WO2004048978A3 (en)	2004-09-02	Diagnostics and therapeutics for diseases associated with bile acid g-protein-coupled receptor 37 (bg37)
WO2005001483A3 (en)	2005-05-12	Methods for diagnisis and differential diagnosis of dementia disorders
WO2004082571A3 (en)	2004-12-23	Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 86 (gpr86)
WO2004044587A3 (en)	2004-09-23	Diagnostics and therapeutics for diseases associated with human endothelial differentiation, sphingolipid g-protein-coupled receptor 5 (edg5)
WO2005040824A3 (en)	2005-06-30	Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24)
WO2005015203A3 (en)	2005-06-16	Diagnostics and therapeutics for diseases associated with g protein-coupled opioid receptor mu 1 (oprm1)